ID: MRFR/HC/6784-HCR | 111 Pages | Published By Rahul Gotadki on March 2023
Cardiomyopathy Medication Market is expected to reach USD 620 Million by 2025 at a CAGR of 4.85%.
$620 Million
4.85%
North America
2020-2030
Cardiomyopathy Medication Market is expected to grow from USD 800.87 Million in 2018 to USD 620 Million by 2030 at a CAGR of 4.85%.
Cardiomyopathy medication is extensively used in North America and Europe and is fast becoming mainstream in Asia-Pacific.
A growing geriatric population and changing lifestyle habits are contributing to the increased incidence of cardiomyopathy. It is the third major cause of heart failure in the US and affects five in 100,000 adults in the country.
Cardiomyopathy Medication Market USP
Increase in number of cardiomyopathy cases and need for lifelong medication to manage the condition.
Market Drivers
Market Restraints
Cardiomyopathy Medication Market SEGMENTATION
By Type
Cardiomyopathy Medication Market By Treatment
Cardiomyopathy Medication Market By End User
Cardiomyopathy Medication Market By Region
Cardiomyopathy Medication Market Key Players
Report Attribute/Metric | Details |
---|---|
Market Size |
|
CAGR | 4.85% (2020-2030) |
Base Year | 2019 |
Forecast Period | 2020-2030 |
Historical Data | 2018 |
Forecast Units | Value (USD Million) |
Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
Segments Covered | By Type, By Treatmen and By End User |
Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
Key Vendors | Pfizer Inc., PhaseBio Pharmaceuticals, Inc., Array Biopharma, Inc., AstraZeneca, Sanofi-Aventis US LLC, Hoffmann-La Roche Ltd, Merck & Co., Inc., Capricor Therapeutics, MyoKardia Janssen Products, LP, Ionis Pharmaceuticals, Inc.,Medtronic Becton And Dickson & Co., Biomerieux, Teva Pharmaceutical Industries Ltd |
Key Market Opportunities | Increase in number of cardiomyopathy cases and need for lifelong medication to manage the condition |
Key Market Drivers |
|
The cardiomyopathy medication market is projected to grow at a 4.85% CAGR between 2020-2030.
The Americas are predicted to command the highest share in the cardiomyopathy medication market.
The cardiomyopathy medication market is predicted to touch USD 620 million by 2025.
Increasing prevalence of hypertension and recent product launches are boosting market growth.
Availability of alternatives and high cost may restrict market growth.